Clinical trials: Depressive Disorder, Major
Major Depressive Disorder (MDD)
Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
This is an 8-week, randomized, double blind, parallel group, 3-arm trial to compare 10 mg/day, 20 mg/day and 40 mg/day as starting doses of vilazodone following a switch from generic SSRIs and SNRIs.
- Trial name
- NCT02015546
- Testing
- Vilazodone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Duke University
Major Depressive Disorder
Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases
The purpose of this study is to determine whether upregulating the left amygdala during positive autobiographical memory recall via real time functional magnetic resonance imaging neurofeedback will lead to an improvement in…
- Trial name
- NCT02079610
- Testing
- real-time fMRI neurofeedback: Amygdala, real-time fMRI neurofeedback: HIPS
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Major Depressive Disorder, Treatment-Resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly.
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Depression
- Trial name
- NCT04821271
- Testing
- TS-161
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)
This randomized, double-blind, placebo-controlled, multicenter, 8-week, clinical trial is designed to assess the efficacy and safety of vilazodone and to evaluate genetic biomarkers of treatment response associated with…
- Trial name
- NCT00683592
- Testing
- vilazodone
- Where
- 9 sites in United States
- Volunteers
- 481 people
- Sponsor
- Forest Laboratories
Depression
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major…
- Trial name
- NCT01072630
- Testing
- Armodafinil
- Where
- 92 sites in United States, Argentina and 8 more
- Volunteers
- 492 people
- Sponsor
- Cephalon
Major Depressive Disorder, Anxiety Disorder
Tapering Off Antidepressants
The purpose of this study is to compare two ways to stop taking an antidepressant medication and determine whether a faster or slower taper is better tolerated.
- Conditions
- Major Depressive Disorder, Anxiety Disorder, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder
- Trial name
- NCT02661828
- Testing
- Two-Week Antidepressant Taper Regimen, One-Week Antidepressant Taper Regimen
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Emory University
Major Depressive Disorder, Post Traumatic Stress Disorder
Positive Processes and Transition to Health
The R61 will be an open trial to determine if Positive Processes and Transition to Health (PATH) engages the proposed targets: unproductive processing, avoidance, and reward deficits in a sample of 45 adults who have experienced…
- Trial name
- PATH (NCT04678232)
- Testing
- Positive Processes and Transition to Health (PATH)
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Case Western Reserve University
Depressive Disorder
Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)
This study is designed to compare the efficacy of oral paroxetine 10 to 40 mg/day (initial dose:10 mg/day) versus placebo administered once daily (after evening meal) for 8 weeks in children and adolescents with major depressive…
- Trial name
- NCT00812812
- Testing
- paroxetine 10mg tablet, paroxetine 20mg tablet
- Where
- 33 sites in Japan
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study of LY2216684 and Warfarin in Healthy Subjects
The purpose of this study is to determine how warfarin might affect LY2216684 and how giving LY2216684 might affect warfarin in the body. Information about any side effects that may occur will also be collected.
- Trial name
- NCT01263119
- Testing
- Warfarin, LY2216684
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Imaging Predictors of Treatment Response in Depression
While there are many effective options for treating a major depressive episode, there are no clinical markers that predict the likelihood of remission with an initial trial of either an antidepressant medication or psychotherapy.
- Trial name
- NCT00367341
- Testing
- escitalopram, Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Emory University
Schizophrenia, Major Depression
Past Pain Experience and Perception of Experimental Pain
Differences in pain perception between subjects with and without psychiatric illness may be influenced by the individual experience, and not primarily by the pathology, although the pathological frame may amplify it.The aim of…
- Trial name
- NCT01575912
- Testing
- experimental pain tests
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Esquirol
Major Depressive Disorder, Depression
rTMS for MDD: 5.5cm Rule vs. F3 Targeting
The purpose of this study is to examine the effects of different treatment locations using repetitive transcranial magnetic stimulation (rTMS) to treat major depressive disorder.
- Trial name
- NCT03378570
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- Nicholas Trapp
Depression
Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder
To evaluate the effectiveness of one algorithm for Major Depression Disorder (MDD) using medications available in the Brazilian Public Healthcare System (SUS), and assessment of the quality of life of these patients.
- Trial name
- NCT02901249
- Testing
- sertraline, Nortriptyline, Lithium
- Volunteers
- 68 people
- Sponsor
- Federal University of Rio Grande do Sul
Depressive Disorder, Major, Cannabis Abuse
Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
Adolescents who are diagnosed with major depressive disorder are often also diagnosed with marijuana dependence. Fluoxetine is an antidepressant medication currently used to treat young people who are diagnosed with major…
- Trial name
- CADY (NCT00149643)
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Neurobiological Bases of Placebo Response in Major Depressive Disorder
We are doing this research study to find out if people who get better while taking a specific kind of antidepressant medication (a selective serotonin reuptake inhibitor, or SSRI) and people who get better while taking placebo…
- Trial name
- NCT01787240
- Testing
- Escitalopram 10mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to…
- Trial name
- NCT03738215
- Testing
- Cariprazine
- Where
- 125 sites in United States, Bulgaria and 5 more
- Volunteers
- 759 people
- Sponsor
- AbbVie
Depression, Depressive Disorder
Electroacupuncture for Major Depression
This study will compare the safety, efficacy, and tolerability of electroacupuncture (EA) and sham electroacupuncture (SA) for the treatment of major depression.
- Trial name
- NCT00071110
- Testing
- Electroacupuncture
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Major Depression
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
Participating subjects are those who are referred for electroconvulsive therapy (ECT) for severe depression who have agreed to the protocol. The control group receives ECT as usual.
- Trial name
- NCT00616759
- Testing
- electroconvulsive therapy, electroconvulsive therapy plus propofol, propofol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Loma Linda University
Major Depressive Disorder, Soft Tissue Discomfort Syndrome
Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome
The objective of this study is to determine the time course of duloxetine efficacy on the symptoms of Major Depressive Disorder (MDD)and on the symptoms of Soft Tissue Discomfort Syndrome(STDS) via use of 24-hour Actigraph™…
- Conditions
- Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
- Trial name
- NCT01035073
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pennsylvania
Major Depressive Disorder, Insomnia
Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon
Hypothesis I: Patients in the SSRI + ramelteon treatment group will achieve remission (defined as an IDS-C30 score of 11 or less) more quickly than those in the SSRI + placebo group.
- Trial name
- TAKEDA (NCT00642694)
- Testing
- Escitalopram, Ramelteon
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Texas Southwestern Medical Center